Staged risk management of candidate drug efficacy: A proposed structure to classify levels of proof within a clinical development programme

International Journal of Pharmaceutical Medicine

Volumn 19, Issue 4, 2005, Pages 227-232

  Smethurst, Dominic ^a   Hughes, Andrew ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PROPOFOL; PURINERGIC RECEPTOR BLOCKING AGENT; RECEPTOR; VINCRISTINE; WARFARIN;

BLEEDING; COMMUNICATION AID; DEEP VEIN THROMBOSIS; DEVICE; DISEASE MARKER; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUSTRY; HEALTH ECONOMICS; HUMAN; MENINGOENCEPHALITIS; MULTIPLE SCLEROSIS; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 33645853493     PISSN: 13649027     EISSN: 13649027     Source Type: Journal    
DOI: 10.2165/00124363-200519040-00004     Document Type: Review

References (8)

1. Choi DW. Exploratory clinical testing of neuroscience drugs. Nat Neurosci 2002; 5 Suppl.: 1023-5
2. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002; 20 Suppl. 3: 1-10
3. Kuhlmann J. Alternative strategies in drug development: clinical pharmacological aspects. Int J Clin Pharmacol Ther 1999; 37: 575-83
4. From test tube to patient: new drug development in the United States. 2nd ed. Besthesda (MD): Department of Health and Human Services, 1995 [online]. Available from URL: http://www.fda.gov/fdac/special/newdrug/ndd_toc.html [Accessed 2005 Sep 30]
5. Centre for Medicines Research [online]. Available from URL: http://www. cmr.org [Accessed 2005 Sep 30]
6. Gordon SM, Brahim JS, Rowan J, et al. Peripheral prostanoid levels and nonsteroidal anti-inflammatory drug analgesia: replicate clinical trials in a tissue injury model. Clin Pharmacol Ther 2002; 72: 175-83
7. Cohen MH, Williams GA, Sridhara R, et al. United States food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-8
8. Gleckman R. What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents. Postgrad Med 2001; 109: 87-91